Blood Test Revolutionizes Post-Surgery Colon Cancer Care

PALO ALTO, CA – February 02, 2026 – A landmark study is poised to change how doctors and patients approach care after colon cancer surgery. Research published in the prestigious Journal of Clinical Oncology has validated a simple blood test that more accurately predicts the risk of cancer recurrence than traditional methods, offering a new level of precision in the fight against the disease.

The study, the largest of its kind for Stage III colon cancer, demonstrates that the Guardant Reveal® liquid biopsy can identify microscopic traces of cancer, known as molecular residual disease (MRD), left behind after surgery. The findings suggest that this technology could soon become a critical tool in personalizing follow-up treatment, potentially sparing thousands of patients from unnecessary chemotherapy while identifying those who need more aggressive intervention.

A Paradigm Shift in Post-Surgical Assessment

For decades, the standard of care for patients with Stage III colon cancer has involved surgical removal of the tumor followed by adjuvant chemotherapy. The decision to recommend chemotherapy, and its intensity, has been guided by the tumor-node-metastasis (TNM) staging system—a method that assesses the size of the original tumor and how far it has spread to lymph nodes. However, this system has long-recognized limitations.

“TNM staging is an imperfect tool,” explained an oncologist not involved with the study. “It groups patients into broad risk categories, leading to a one-size-fits-all approach. As a result, we overtreat many patients who may have already been cured by surgery, subjecting them to the toxic side effects of chemotherapy, while we undertreat others whose cancer is destined to return.”

This new study, a collaboration between Guardant Health, Mayo Clinic, and the Alliance for Clinical Trials in Oncology, directly addresses this challenge. In a trial involving more than 2,000 patients, researchers used the Guardant Reveal test to analyze blood samples taken after surgery but before the start of chemotherapy. They found that about 20 percent of patients still had detectable circulating tumor DNA (ctDNA) in their bloodstream.

The presence of this ctDNA was a powerful predictor of the future. These patients had a four-to-six-fold higher rate of disease recurrence or death compared to those with no detectable ctDNA. Even more striking, the test identified high-risk individuals whom traditional staging would have missed. Patients with smaller tumors or fewer affected lymph nodes had an over six-fold higher risk of recurrence if their blood test was positive.

“The data suggest that not only the presence of ctDNA, but the amount of ctDNA, as identified by Guardant Reveal may help refine risk beyond standard TNM staging, and could be used to guide adjuvant treatment and surveillance decisions,” said Frank Sinicrope, MD, professor at Mayo Clinic and the study's principal investigator. “ctDNA testing after surgery improves the accuracy of estimating a patient’s risk of cancer recurrence, enabling more tailored recommendations.”

Hope and Clarity for Patients

For anyone who has undergone cancer surgery, the most pressing question is often the most difficult to answer: “Am I cured?” The period after surgery is filled with anxiety, as patients wait to see if the cancer will return. The Guardant Reveal test promises to provide a clearer, more personalized answer.

“This large study adds to growing evidence that ctDNA testing with Guardant Reveal after surgery helps answer the question patients care about most: Am I really cancer-free?” said Dr. Craig Eagle, Guardant Health Chief Medical Officer. “Personalizing care after surgery is essential as clinicians and patients decide what comes next.”

By identifying patients with a truly low risk of recurrence (a negative ctDNA test), doctors may be able to confidently recommend de-escalating or even forgoing adjuvant chemotherapy. This would spare patients from debilitating side effects like nausea, fatigue, and nerve damage, significantly improving their quality of life. Conversely, for the 20% of patients with a positive test, the knowledge provides a critical opportunity to act. It empowers them and their oncologists to consider more intensive chemotherapy, closer surveillance, or enrollment in clinical trials for novel therapies designed to eradicate the remaining cancer cells.

The Technology and Competitive Landscape

The science behind Guardant Reveal is part of a rapidly advancing field known as liquid biopsy. The test works by detecting both genomic and epigenomic alterations—changes in the cancer's DNA and how it's packaged—that are shed from tumor cells into the bloodstream. A key feature of the Guardant Reveal test is that it is “tissue-free,” meaning it does not require a sample of the patient's surgically removed tumor to function. This simplifies the logistical process, potentially speeding up turnaround times and making the test more accessible.

This approach contrasts with some other prominent MRD tests on the market, such as Natera's Signatera, which is “tumor-informed.” A tumor-informed test first analyzes a patient's tumor tissue to identify a unique set of mutations, then creates a personalized blood test to track those specific markers. While some experts argue that this personalization may offer higher sensitivity, the tissue-free approach provides a significant advantage when a tumor sample is unavailable or of poor quality.

The clinical oncology community is actively evaluating both approaches. Large-scale studies like the GALAXY trial, which used the tumor-informed Signatera test, have also shown powerful prognostic results in colorectal cancer, confirming the overall validity of using ctDNA to guide care. The ultimate choice of test may depend on individual clinical circumstances, but the growing body of evidence for both types underscores a fundamental shift toward molecularly-guided cancer management.

From Lab to Clinic: The Path to Widespread Adoption

For any diagnostic innovation to make a real-world impact, it must be both clinically validated and accessible. The publication in a top-tier journal provides strong validation, but the path to routine use depends on two other factors: reimbursement and integration into clinical guidelines.

Guardant Health has already achieved a major milestone on this front. Guardant Reveal is covered by Medicare for guiding adjuvant therapy decisions and for recurrence monitoring in colorectal cancer patients, removing a significant financial barrier for a large portion of the patient population. This decision signals growing recognition by payors of the test's clinical utility.

However, the final step is proving that using the test to change treatment actively improves outcomes. While this study confirms the test's powerful prognostic ability to predict recurrence, ongoing interventional trials like the PEGASUS and ACT-3 studies are designed to prove its prescriptive value. These trials are randomizing ctDNA-positive patients to receive either standard care or intensified treatment to determine if acting on the test results leads to longer, healthier lives.

The results of these ongoing trials will be crucial for incorporating ctDNA testing into official treatment guidelines from organizations like the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO). With strong data, broad reimbursement, and a clear benefit to patients, this new generation of blood tests is set to become an indispensable part of modern oncology, transforming the journey for countless individuals facing a cancer diagnosis.